耳鼻咽喉科・頭頸部外科85巻7号

2013年06月発行

特集 分子標的薬時代の耳鼻咽喉科診療―処方するとき，服用患者を診るときのポイント

≪頭頸部癌に対する分子標的薬治療≫

セツキシマブの特性と頭頸部癌への処方の実際

著者： 榎田智弘¹ 田原信¹

所属機関： ¹国立がん研究センター東病院頭頸部内科

ページ範囲：P.480 - P.487

文献概要

POINT

●頭頸部癌の治療において分子標的薬セツキシマブは，生命予後の改善だけでなく，毒性の軽減にも配慮した使用も期待されている。

●実際の使用に関しては，放射線療法との併用やほかの化学療法（殺細胞薬）との併用などさまざまな使用方法が確立されつつある。また現在も多くの臨床試験によりその有効性が検証されている。

●治療に伴う毒性が従来の殺細胞薬とは異なるため，セツキシマブによる治療効果を最大限に享受できるよう，これらの毒性への適切な対応が求められている。

参考文献

1）財団法人がん研究振興財団．「がんの統計」編集委員会/編：がんの統計'09．2010

2）Ang KK, et al：Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Research 62：7350-7356, 2002

3）Pignon JP, et al：Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma：three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355：949-955, 2000

4）Browman GP, et al：Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer：a systematic review of the published literature with subgroup analysis. Head Neck 23：579-589, 2001

5）Bonner JA, et al：Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer：5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncology 11：21-28, 2010

6）Bonner JA, et al：Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 354：567-578, 2006

7）Okano S, et al：Phase Ⅱ study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck. Jap J Clin Oncol 43：476-482, 2013

8）Ang KZ, QE；Rosenthal, DI：A randomized phase Ⅲ trial（RTOG 0522）of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage Ⅲ-Ⅳ head and neck squamous cell carcinomas（HNC）. J Clin Oncol 2011；29.

9）Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer. http://clinicaltrialsgov/show/NCT01302834.

10）Lefebvre JL, et al：Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation：the TREMPLIN randomized phase Ⅱ study. J Clin Oncol 31：853-859, 2013

11）Bernier J, et al：Defining risk levels in locally advanced head and neck cancers：a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC（#22931）and RTOG（#9501）. Head Neck 27：843-850, 2005

Physics 69：S13, 2007

13）RTOG 0920：A Study of Postoperative Radiation Therapy（IMRT）＋/－ Cetuximab for Locally-advanced Resected Head and Neck Cancer. http://clinicaltrialsgov/ct2/show/NCT01311063.

14）Vermorken JB, et al：Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 359：1116-1127, 2008

15）Yoshino T, et al：Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck：Results of a Phase Ⅱ Trial. Jap J Clin Oncol 2013

16）Peron J, et al：Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Anti-cancer Drugs 23：996-1001, 2012

17）Vermorken JB, et al：Open-label, uncontrolled, multicenter phase Ⅱ study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25：2171-2177, 2007

18）Argiris A, et al：Cetuximab and bevacizumab：preclinical data and phase Ⅱ trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of oncology：official journal of the European Society for Medical Oncology/ESMO 24：220-255, 2013

19）Study of Sorafenib/Cetuximab in Head and Neck Cancer. http://clinicaltrialsgov/ct2/show/NCT00815295?term=NCT00815295&rank=1.

20）Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy. http://clinicaltrialsgov/ct2/show/NCT01256385?term=NCT01256385&rank=1.

21）Zwicker F, et al：IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol 187：32-38, 2011

22）Balermpas P, et al：Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck：feasibility and first efficacy results. Inter J Radiat Oncol Phys 83：e377-383, 2012

23）Lacouture ME, et al：Skin toxicity evaluation protocol with panitumumab（STEPP）, a phase Ⅱ, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28：1351-1357, 2010

24）Izzedine H, et al：Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol 73：213-219, 2010

25）Lajer H, et al：Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 56：535-542, 2005